Related references
Note: Only part of the references are listed.Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Opposing Synaptic Regulation of Amyloid-β Metabolism by NMDA Receptors In Vivo
Deborah K. Verges et al.
JOURNAL OF NEUROSCIENCE (2011)
5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment
Fei Shen et al.
NEUROPHARMACOLOGY (2011)
APOE Predicts Amyloid-Beta but Not Tau Alzheimer Pathology in Cognitively Normal Aging
John C. Morris et al.
ANNALS OF NEUROLOGY (2010)
Deletion of M1 Muscarinic Acetylcholine Receptors Increases Amyloid Pathology In Vitro and In Vivo
Albert A. Davis et al.
JOURNAL OF NEUROSCIENCE (2010)
Blowing hot and cold over depression and cognitive impairment
Yonas E. Geda
NEUROLOGY (2010)
Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment
Vonetta M. Dotson et al.
NEUROLOGY (2010)
Depressive symptoms and risk of dementia The Framingham Heart Study
J. S. Saczynski et al.
NEUROLOGY (2010)
Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
John C. Morris et al.
ARCHIVES OF NEUROLOGY (2009)
Antidepressants and dementia
Lars Vedel Kessing et al.
JOURNAL OF AFFECTIVE DISORDERS (2009)
Synaptic NMDA Receptor Activation Stimulates α-Secretase Amyloid Precursor Protein Processing and Inhibits Amyloid-β Production
Sarah E. Hoey et al.
JOURNAL OF NEUROSCIENCE (2009)
Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice
Ping Yan et al.
JOURNAL OF NEUROSCIENCE (2009)
Dose translation from animal to human studies revisited
Shannon Reagan-Shaw et al.
FASEB JOURNAL (2008)
Will anti-amyloid therapies work for Alzheimer's disease?
Peter H. St George-Hyslop et al.
LANCET (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease
M. I. Geerlings et al.
NEUROLOGY (2008)
Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice
Lisa McConlogue et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Catecholaminergic control of mitogen-activated protein kinase signaling in paraventricular neuroendocrine neurons in vivo and in vitro:: A proposed role during glycemic challenges
Arshad M. Khan et al.
JOURNAL OF NEUROSCIENCE (2007)
Serotonin and neuronal growth factors - a convergence of signaling pathways
Daniel S. Cowen
JOURNAL OF NEUROCHEMISTRY (2007)
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice
Rhonda L. Nelson et al.
EXPERIMENTAL NEUROLOGY (2007)
Effects of neurosteroids on glucocorticoid receptor-mediated gene transcription in LMCAT cells - A possible interaction with psychotropic drugs
Agnieszka Basta-Kaim et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2007)
M1 muscarinic agonists target major hallmarks of Alzheimer's disease - an update
Abraham Fisher
CURRENT ALZHEIMER RESEARCH (2007)
[11]PIB in a nondemented population -: Potential antecedent marker of Alzheimer disease
M. A. Mintun et al.
NEUROLOGY (2006)
Depression and risk for Alzheimer disease - Systematic review, meta-analysis, and metaregression analysis
RL Ownby et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Novel DNA and RNA inhibitors of metallo-β-lactamase
RW Shaw et al.
FASEB JOURNAL (2006)
The neuropeptide PACAP promotes alpha-secretase pathway for processing Alzheimer amyloid precursor protein
E Kojro et al.
FASEB JOURNAL (2006)
ERK1/2 is an endogenous negative regulator of the γ-secretase activity
SK Kim et al.
FASEB JOURNAL (2005)
Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro
M Pákáski et al.
NEUROCHEMISTRY INTERNATIONAL (2005)
The stress system in the human brain in depression and neurodegeneration
DF Swaab et al.
AGEING RESEARCH REVIEWS (2005)
Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease:: Relationships to β-amyloid deposition and neurotransmitter abnormalities
A Savonenko et al.
NEUROBIOLOGY OF DISEASE (2005)
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B
WE Klunk et al.
ANNALS OF NEUROLOGY (2004)
Untreated depression and hippocampal volume loss
YI Sheline et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease
OL Lopez et al.
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES (2003)
Depression as a risk factor for Alzheimer disease - The MIRAGE study
RC Green et al.
ARCHIVES OF NEUROLOGY (2003)
Extracellular amyloid formation and associated pathology in neural grafts
M Meyer-Luehmann et al.
NATURE NEUROSCIENCE (2003)
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds
I Skoog et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2003)
Effect of a 5-HT2C serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs
AA Arjona et al.
BRAIN RESEARCH (2002)
Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling
J Pouysségur et al.
BIOCHEMICAL PHARMACOLOGY (2002)
M1 muscarinic acetylcholine receptors activate extracellular signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices
JL Berkeley et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2001)
Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease
JC Morris et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2001)
Share Paper
